CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptor
The FASEB Journal · 2025
DOI: 10.1096/fj.202400490r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Rajendra Kumar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Prostate Cancer/Genitourologic Program, Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimo…. Hauptthemen laut MEDLINE: Karyopherins, Receptors, Androgen, Prostatic Neoplasms, Receptors, Cytoplasmic and Nuclear. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, DOD | USA | MEDCOM | CDMRP | DOD Prostate Cancer Research Program (PCRP), Prostate Cancer Foundation (PCF).
Abstract (Originalsprache)
Among the known nuclear exportins, CRM1 is the most studied prototype. Dysregulation of CRM1 occurs in many cancers, hence, understanding the role of CRM1 in cancer can help in developing synergistic therapeutics. The study investigates how CRM1 affects prostate cancer growth and survival. It examines the role of CRM1 in regulating androgen receptor (AR) and DNA repair in prostate cancer. Our findings reveal that CRM1 influences AR mRNA and protein stability, leading to a loss of AR protein upon CRM1 inhibition. Furthermore, it highlights the involvement of HSP90 alpha, a known AR chaperone, in the CRM1‐dependent regulation of AR protein stability. The combination of CRM1 inhibition with an HSP90 inhibitor demonstrates potent effects on decreasing prostate cancer cell growth and survival. The study further explores the influence of CRM1 on DNA repair proteins and proposes a strategy of combining CRM1 inhibitors with DNA repair pathway inhibitors to decrease prostate cancer growth. Overall, the findings suggest that CRM1 plays a crucial role in prostate cancer growth, and a combination of inhibitors targeting CRM1 and DNA repair pathways could be a promising therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Prostate Cancer/Genitourologic Program, Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Rajendra Kumar, Janet Mendonca, Abhishek Shetty, Yuhan Yang, Olutosin Owoyemi, Lillian Wilson, Kavya Boyapati, Deven Topiwala, Naiju Thomas, Huong Nguyen, Jun Luo, Channing J Paller, Samuel R Denmeade, Michael A Carducci, Sushant K Kachhap
Förderung
- NCI NIH HHS
- DOD | USA | MEDCOM | CDMRP | DOD Prostate Cancer Research Program (PCRP)
- Prostate Cancer Foundation (PCF)
- Patrick C. Walsh Prostate Cancer Research Fund (Patrick C Walsh Prostate Cancer Research Fund)
- NIH NCI
- DOD Prostate Cancer Research Program
Zitieren
APA
Kumar, R., Mendonca, J., Shetty, A., Yang, Y., Owoyemi, O., Wilson, L., Boyapati, K., Topiwala, D., Thomas, N., Nguyen, H., Luo, J., Paller, C. J., Denmeade, S. R., Carducci, M. A., & Kachhap, S. K. (2025). CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptor. The FASEB Journal. https://doi.org/10.1096/fj.202400490r
Vancouver
Kumar R, Mendonca J, Shetty A, Yang Y, Owoyemi O, Wilson L, et al. CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptor. The FASEB Journal. 2025. doi:10.1096/fj.202400490r
BibTeX
@article{Kumar2025,
author = {Kumar, Rajendra and Mendonca, Janet and Shetty, Abhishek and Yang, Yuhan and Owoyemi, Olutosin and Wilson, Lillian and Boyapati, Kavya and Topiwala, Deven and Thomas, Naiju and Nguyen, Huong and Luo, Jun and Paller, Channing J and Denmeade, Samuel R and Carducci, Michael A and Kachhap, Sushant K},
title = {CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptor},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202400490r}
}
EUVIMED